179 related articles for article (PubMed ID: 16784459)
1. Insight into the binding mode for cyclopentapeptide antagonists of the CXCR4 receptor.
Våbenø J; Nikiforovich GV; Marshall GR
Chem Biol Drug Des; 2006 May; 67(5):346-54. PubMed ID: 16784459
[TBL] [Abstract][Full Text] [Related]
2. A minimalistic 3D pharmacophore model for cyclopentapeptide CXCR4 antagonists.
Våbenø J; Nikiforovich GV; Marshall GR
Biopolymers; 2006; 84(5):459-71. PubMed ID: 16552740
[TBL] [Abstract][Full Text] [Related]
3. Targeting HIV-1 through molecular modeling and docking studies of CXCR4: leads for therapeutic development.
Singh S; Malik BK; Sharma DK
Chem Biol Drug Des; 2007 Mar; 69(3):191-203. PubMed ID: 17441905
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ligand-based and receptor-based virtual screening of HIV entry inhibitors for the CXCR4 and CCR5 receptors using 3D ligand shape matching and ligand-receptor docking.
Pérez-Nueno VI; Ritchie DW; Rabal O; Pascual R; Borrell JI; Teixidó J
J Chem Inf Model; 2008 Mar; 48(3):509-33. PubMed ID: 18298095
[TBL] [Abstract][Full Text] [Related]
5. Rational design of conformationally constrained cyclopentapeptide antagonists for C-x-C chemokine receptor 4 (CXCR4).
Mungalpara J; Thiele S; Eriksen Ø; Eksteen J; Rosenkilde MM; Våbenø J
J Med Chem; 2012 Nov; 55(22):10287-91. PubMed ID: 23043442
[TBL] [Abstract][Full Text] [Related]
6. Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
Subramanian G; Paterlini MG; Larson DL; Portoghese PS; Ferguson DM
J Med Chem; 1998 Nov; 41(24):4777-89. PubMed ID: 9822548
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach.
Ueda S; Kato M; Inuki S; Ohno H; Evans B; Wang ZX; Peiper SC; Izumi K; Kodama E; Matsuoka M; Nagasawa H; Oishi S; Fujii N
Bioorg Med Chem Lett; 2008 Jul; 18(14):4124-9. PubMed ID: 18539453
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions.
Yoshikawa Y; Kobayashi K; Oishi S; Fujii N; Furuya T
Bioorg Med Chem Lett; 2012 Mar; 22(6):2146-50. PubMed ID: 22365757
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening.
Pérez-Nueno VI; Pettersson S; Ritchie DW; Borrell JI; Teixidó J
J Chem Inf Model; 2009 Apr; 49(4):810-23. PubMed ID: 19358515
[TBL] [Abstract][Full Text] [Related]
11. Binding modes of dihydroquinoxalinones in a homology model of bradykinin receptor 1.
Ha SN; Hey PJ; Ransom RW; Harrell CM; Murphy KL; Chang R; Chen TB; Su DS; Markowitz MK; Bock MG; Freidinger RM; Hess FJ
Biochem Biophys Res Commun; 2005 May; 331(1):159-66. PubMed ID: 15845373
[TBL] [Abstract][Full Text] [Related]
12. Development of a 3D model for the human cannabinoid CB1 receptor.
Salo OM; Lahtela-Kakkonen M; Gynther J; Järvinen T; Poso A
J Med Chem; 2004 Jun; 47(12):3048-57. PubMed ID: 15163186
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
14. Expression and functional characterization of mutant human CXCR4 in insect cells: role of cysteinyl and negatively charged residues in ligand binding.
Zhou H; Tai HH
Arch Biochem Biophys; 2000 Jan; 373(1):211-7. PubMed ID: 10620340
[TBL] [Abstract][Full Text] [Related]
15. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
Zhou Z; Bates M; Madura JD
Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists.
Dastmalchi S; Hamzeh-Mivehroud M; Ghafourian T; Hamzeiy H
J Mol Graph Model; 2008 Jan; 26(5):834-44. PubMed ID: 17561422
[TBL] [Abstract][Full Text] [Related]
17. Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor.
Fleck BA; Chen C; Yang W; Huntley R; Markison S; Nickolls SA; Foster AC; Hoare SR
Biochemistry; 2005 Nov; 44(44):14494-508. PubMed ID: 16262250
[TBL] [Abstract][Full Text] [Related]
18. Impact of the CXCR4 structure on docking-based virtual screening of HIV entry inhibitors.
Planesas JM; Pérez-Nueno VI; Borrell JI; Teixidó J
J Mol Graph Model; 2012 Sep; 38():123-36. PubMed ID: 23079643
[TBL] [Abstract][Full Text] [Related]
19. Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists.
Lavecchia A; Cosconati S; Novellino E
J Med Chem; 2005 Apr; 48(7):2480-92. PubMed ID: 15801838
[TBL] [Abstract][Full Text] [Related]
20. Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).
Oishi S; Fujii N
Org Biomol Chem; 2012 Aug; 10(30):5720-31. PubMed ID: 22517031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
